PRESS RELEASE published on 07/04/2025 at 07:00, 1 year 4 months ago Inside Information / Other news releases Innate Pharma discloses number of shares and voting rights as of July 3, 2025, in accordance with French regulations. Total shares: 92,183,523. Total voting rights: 92,962,943 (theoretical) and 92,944,368 (exercisable) Voting Rights Shares French Regulations Financial Disclosure Innate Pharma
BRIEF published on 06/17/2025 at 07:05, 1 year 4 months ago Innate Pharma to Participate in Key Investor Conferences Biotechnology Investor Conferences Healthcare Immunotherapy Innate Pharma
BRIEF published on 06/17/2025 at 07:05, 1 year 4 months ago Innate Pharma participera à des conférences d'investisseurs clés Biotechnologie Immunothérapie Soins De Santé Conférences D'investisseurs Innate Pharma
PRESS RELEASE published on 06/17/2025 at 07:00, 1 year 4 months ago Inside Information / Other news releases Innate Pharma to participate in H.C. Wainwright and Wolfe Research healthcare conferences showcasing their innovative immunotherapy approaches. Global biotech company expanding portfolio Biotechnology Immunotherapy Clinical-stage Innate Pharma Healthcare Conferences
BRIEF published on 06/13/2025 at 07:05, 1 year 4 months ago Innate Pharma's IPH6501 Shows Potential in Lymphoma Treatment Innate Pharma Preclinical Results IPH6501 Lymphoma R-CHOP
BRIEF published on 06/13/2025 at 07:05, 1 year 4 months ago L'IPH6501 d'Innate Pharma montre un potentiel dans le traitement du lymphome Innate Pharma Résultats Précliniques IPH6501 R-CHOP Lymphome
PRESS RELEASE published on 06/13/2025 at 07:00, 1 year 4 months ago Inside Information / Other news releases Innate Pharma highlights preclinical antitumor activity of IPH6501 in DLBCL and FL at the 2025 EHA Congress, presenting potent efficacy in in vitro and in vivo models with R-CHOP combination Preclinical Data EHA Congress Innate Pharma Antitumor Activity IPH6501
BRIEF published on 05/13/2025 at 07:05, 1 year 5 months ago Innate Pharma publie ses résultats du premier trimestre 2025 Résultats Financiers Essais Cliniques Innate Pharma Investissement Sanofi Lacutamab FDA
BRIEF published on 05/13/2025 at 07:05, 1 year 5 months ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 5 months ago Informations privilégiées / Communiqué sur comptes, résultats Innate Pharma annonce ses résultats financiers du premier trimestre 2025 et les avancées de son portefeuille, incluant des investissements et des études cliniques. Une conférence téléphonique est prévue à 14h00 CEST Résultats Financiers Conférence Téléphonique Portefeuille Études Cliniques Innate Pharma
Published on 11/11/2026 at 00:40, 14 minutes ago Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 1 hour 24 minutes ago CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 1 hour 54 minutes ago Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 1 hour 54 minutes ago Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 1 hour 54 minutes ago Condor Agrees to Short Extension of Lucero Closing Payment with ELEMENT79 and Provides Huiñac Punta Drill Program Update
Published on 11/11/2026 at 00:15, 39 minutes ago Lean Focus Launches Asia Pacific: Local Expertise. Global Impact.
Published on 11/10/2026 at 23:15, 1 hour 39 minutes ago GSMA MWC26 Doha welcomed over 10,000 attendees, as world-first ITU co-location puts MENA at the centre of global connectivity policy and innovation
Published on 11/10/2026 at 19:21, 5 hours 32 minutes ago ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Published on 11/10/2026 at 18:00, 6 hours 54 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 7 hours 9 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 7 hours 19 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 7 hours 22 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
